Eikesdal Hans Petter, Dahl Olav, Straume Oddbjørn, Akslen Lars A
Avdeling for kreftbehandling og strålefysikk, Institutt for indremedisin, Haukeland Universitetsskehus, Bergen.
Tidsskr Nor Laegeforen. 2004 Aug 12;124(15):1919-22.
Tumour angiogenesis and lymphangiogenesis are important new areas of cancer research. In this paper we highlight the central aspects of these processes and describe new therapies directed at the tumour vasculature. We also present some of our own data.
Data from key papers in international journals on tumour angiogenesis and lymphangiogenesis are cited and discussed.
Research on tumour angiogenesis and lymphangiogenesis has increased dramatically over the last 30 years. Today, this knowledge is being used to predict the aggressiveness of malignant tumours and to design compounds which can halt the angiogenesis process and affect tumour growth.
Insight into how angiogenesis and lymphangiogenesis are regulated in malignant neoplasms is important to the understanding of tumour biology. Currently, numerous clinical trials are conducted with angiogenesis inhibitors; the first completed trials indicate that tumour growth may be retarded in some cancer entities.
肿瘤血管生成和淋巴管生成是癌症研究的重要新领域。在本文中,我们重点介绍这些过程的核心方面,并描述针对肿瘤脉管系统的新疗法。我们还展示了我们自己的一些数据。
引用并讨论了国际期刊上关于肿瘤血管生成和淋巴管生成的关键论文数据。
在过去30年中,对肿瘤血管生成和淋巴管生成的研究急剧增加。如今,这些知识正被用于预测恶性肿瘤的侵袭性,并设计能够阻止血管生成过程并影响肿瘤生长的化合物。
深入了解恶性肿瘤中血管生成和淋巴管生成的调控方式对于理解肿瘤生物学很重要。目前,正在进行大量关于血管生成抑制剂的临床试验;首批完成的试验表明,在某些癌症实体中肿瘤生长可能会受到抑制。